Survey about immunotherapy for lung cancer patients
Part of Cancer, Lungs & breathing clinical trials.
This study is a survey to learn about the experiences and feelings of people with non-small cell lung cancer who are taking immunotherapy drugs. The goal is to understand how you're doing on treatment, which can help improve care for others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with non-small cell lung cancer.
- You are currently on an immunotherapy drug (like Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, or Pembrolizumab) and have already received at least one dose.
- You can give your consent to join the study, either by yourself or with a family member or friend helping you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy medicine to standard chemotherapy after surgery can improve outcomes for some people with non-small cell lung cancer. It may help by boosting the immune system to reduce the chance the cancer comes back.
This study is looking at how the immune system responds to immunotherapy in people with advanced non-small cell lung cancer. By collecting sputum (mucus from your lungs) and blood samples, researchers hope to find clues that could help predict treatment outcomes.
This study collects and analyzes medical information (and sometimes tissue samples) to help personalize treatment plans for advanced non-small-cell lung cancer using immunotherapy. It may help researchers find which people benefit most and how treatment can be better matched to each patient.
This study aims to understand the care needs of people with lung cancer who are receiving or have received immunotherapy. By participating, you can help improve support for other patients going through similar treatment.
This study looks at how patients with advanced lung cancer feel during their treatment, which combines chemotherapy, radiation, and an immunotherapy drug. The goal is to understand and improve quality of life during therapy.
This study tests a combination of chemotherapy and immunotherapy in people with advanced non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see how well this treatment works in patients with different levels of daily activity.
Hear when a new Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.